Plain English Summary

Not provided at time of registration

Trial website

http://www.eurotherm3235trial.eu

Contact information

Type

Scientific

Primary contact

Prof Peter JD Andrews

ORCID ID

Contact details

Critical Care Unit
Ward 20
Western General Hospital
Crewe Road
Edinburgh
EH4 2XU
United Kingdom
p.andrews@ed.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

Protocol version 8 dated 9/5/12

Study information

Scientific title

European Society of Intensive Care Medicine study of therapeutic hypothermia (32 - 35°C) for intracranial pressure (ICP) reduction after traumatic brain injury

Acronym

Eurotherm3235Trial

Study hypothesis

Current hypothesis as of 01/07/2009:
Patients treated with therapeutic hypothermia (32 - 35°C) will have reduced morbidity and mortality rates compared to those receiving standard care alone after traumatic brain injury (TBI).

More information can be found at http://www.eurotherm3235trial.eu

Initial information at time of registration:
Does therapeutic hypothermia (33 - 35°C) reduce death and disability after intracranial hypertension due to traumatic brain injury?

As of 01/07/2009 this record has been extensively updated to reflect recent protocol changes. All changes can be found under the relevant field with the above update date. Please note that at this time, the anticipated trial dates have also been updated; the initial trial dates were as follows:
Anticipated start date: 01/01/2009
Anticipated end date: 30/07/2013

Please note that as of 14/08/2012, this record has been updated extensively. All changes can be found under the relevant field with the above update date.
The following changes were also made:
1. The Scientific title was changed from 'European Society of Intensive Care Medicine study of therapeutic hypothermia (32 - 35°C) for intracranial pressure (ICP) reduction after traumatic brain injury' to 'European study of therapeutic hypothermia (32-35˚C) for intracranial pressure reduction after traumatic brain injury’ '
2. The target number of participants was changed from 1800 to 600
3. The anticipated end date was changed from 07/02/2013 to 31/07/2017
4. France, the Netherlands and Poland were removed from the countries of recruitment, and Belguim, Estonia, Greece, Hungary, India, Ireland, Russian Federation, Spain and United Arab Emirates were added to the countries of recruitment.

Ethics approval

All trial centres will seek ethical approval before recruiting patients. Ethical approval has been obtained in both Scotland and England in June 09.

Study design

Prospective randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Patient information can be found at http://www.eurotherm3235trial.eu/information/index.phtml

Condition

Traumatic brain injury complicated by increased intracranial pressure

Intervention

Current information as of 01/07/2009:
Intervention Group: Usual traumatic brain injury management with therapeutic hypothermia (32 - 35°C) for at least 48 hours. The depth of hypothermia will be dependent on ICP control with a higher ICP warranting a lower target temperature. Hypothermia will be induced rapidly using 20 - 30 ml/kg refrigerated saline (0.9%) over 20 - 30 minutes. Hypothermia will then be maintained by using the cooling technique that is routinely used at each recruiting centre.

Control Group: Usual traumatic brain injury management.

Total duration of follow up: 6 months

Initial information at time of registration:
Intervention group: Traumatic brain injury management (Brain Trauma Foundation guidelines) + hypothermia (33 - 35°C) for 48 hours (at least) and guided by ICP response to slow rewarming at 0.3°C/hour. Each centre will use 20 ml per kg of Hartman's solution at 4°C and then a cooling technique available at that centre (a priori sub group analysis may be effectiveness of device type on outcome) and previous experience of the use of hypothermia will be essential.

Control group: Traumatic brain injury management in line with the Brain Trauma Foundation guidelines.

Total duration of follow-up: 6 months

Intervention type

Other

Phase

Not Applicable

Drug names

Primary outcome measures

Outcome at 6 months using the extended Glasgow Outcome Score (GOSE) questionnaire

Secondary outcome measures

Current information as of 01/07/2009:
1. 6-month mortality rate
2. Intracranial pressure (ICP) control
3. Incidence of Pneumonia across both groups
4. Length of stay in the Intensive Care Unit (ICU) and Hospital
5. Modified Oxford Handicap Scale score at one month, discharge from the randomising hospital or death, whichever occurs first
6. Correlation between the predicted outcome using the modified Oxford handicap scale at hospital discharge and the GOSE Score at 6 months post injury
7. Health economics (dependent on additional external funding)

Other planned analyses:
A priori sub group analysis will be presented testing the relationship between minimisation factors including; age < 45 years, admission post resuscitation GCS motor score <2, time from injury <12 hours and outcome. The analysis will test for interaction effects, and stricter levels of statistical significance (p<0.01) will be sought, reflecting the exploratory nature of these subgroup analyses. Only the primary outcome measure will be used in these analyses.

Other exploratory and observational studies will be conducted by some centres. These sub-studies will be run by local Investigators and will require approval by the trial management and steering committees together with further ethical approval. All sub-studies must also have secured external funding.

Initial information at time of registration:
1. ICP control, assessed by use of additional stage 2 therapies and/or escalation to stage three therapies, episodes of ICP >20 mmHg and duration ICP >20 mmHg
2. Length of intensive care unit (ICU) and hospital stay
3. Head Injury Related Early Outcome Scale (HIREOS) at 21 days
4. Mortality

Other planned analyses:
A priori sub group analysis will be testing the relationship between minimisation factors, including age less than and age older than 45 years, presence of cerebral contusion on CT scanning, admission post resuscitation GCS <5, gender, cooling technology, and outcome. Stricter levels of statistical significance (p <0.01) will be sought, reflecting the exploratory nature of these subgroup analyses. Primary outcome measure only will be used in these analyses.

Other exploratory, observational studies will be conducted by some centres and will include assessment of the genetics of responsiveness to hypothermia (to be lead by Professor Menon), modulation of inflammation (including response to intercurrent infection) and effect upon cerebral vascular autoregulation. There are likely to be other sub-studies run by centre PIs and all will require approval by the steering committee and will have identified external funding.

Overall trial start date

01/09/2009

Overall trial end date

31/07/2017

Reason abandoned

Eligibility

Participant inclusion criteria

Current inclusion criteria as of 14/08/2012:
1. Believed to be legal age for consent to take part in research, either sex
2. Primary closed traumatic brain injury
3. Raised ICP greater than 20 mmHg for greater than or equal to 5 minutes after first line treatments with no obvious reversible cause e.g. patient position, coughing, inadequate sedation
4. Less than or equal to 10 days from the initial head injury
5. Cooling device or technique available for greater than 48 hours
6. Core temperature greater than or equal to 36°C (at the time of randomisation)
7. An abnormal computed tomography (CT) scan of the brain. This is defined as one that shows haematoma, contusion, swelling, herniation or compressed basal cisterns.

Previous inclusion criteria as of 01/07/2009 and until 14/08/2012:
1. Believed to be legal age for consent to take part in research to 65 years of age, either sex
4. Less than or equal to 72 hours from the initial head injury

Initial information at time of registration (2008):
1. Adults aged 16 - 65 years, both males and females
2. Primary, closed traumatic brain injury
3. An abnormal computed tomography (CT) scan of brain, Marshall grade greater than 1
4. Refractory increased intracranial pressure (ICP) greater than 20 mmHg for at least 30 minutes (refractory to first line interventions including mechanical ventilation, sedation, analgesia ± muscle relaxant, head of bed elevation, with monitoring of CVP and invasive arterial pressure)
5. Core temperature greater than 36°C (at the time of randomisation)
6. Cooling device or technique available for greater than 48 hours

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

600

Participant exclusion criteria

Current information as of 01/07/2009:
1. Patient already receiving therapeutic hypothermia treatment
2. Administration of barbiturate infusion prior to randomisation
3. Unlikely to survive for the next 24 hours in the opinion of the ICU Consultant or Consultant Neurosurgeon treating the patient
4. Temperature less than or equal to 34°C at hospital admission
5. Pregnancy

Initial information at time of registration:
1. Patients with bilateral fixed and dilated pupils
2. Unable to monitor ICP or patients with ICP less than 20 mmHg
3. Patients who have received barbiturates prior to randomisation
4. Where there is documented brainstem involvement
5. Moribund condition on admission

Recruitment start date

01/09/2009

Recruitment end date

31/07/2017

Locations

Countries of recruitment

Belgium, Estonia, Germany, Greece, Hungary, India, Ireland, Italy, Russian Federation, Spain, United Arab Emirates, United Kingdom

Trial participating centre

Critical Care Unit, Ward 20
Edinburgh
EH4 2XU
United Kingdom

Sponsor information

Organisation

University of Edinburgh and NHS Lothian (UK)

Sponsor details

Queen’s Medical Research Institute
Room E106
47 Little France Crescent
Edinburgh
EH16 4SA
United Kingdom
+44 (0)131 242 9461
marise.bucukoglu@ed.ac.uk

Sponsor type

University/education

Website

http://www.accord.ed.ac.uk

Funders

Funder type

Research organisation

Funder name

The European Society of Intensive Care Medicine (Belgium)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Funder name

The National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

1. 2011 protocol in http://www.ncbi.nlm.nih.gov/pubmed/21226939
2. 2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/24004918

Publication citations

  1. Protocol

    Andrews PJ, Sinclair HL, Battison CG, Polderman KH, Citerio G, Mascia L, Harris BA, Murray GD, Stocchetti N, Menon DK, Shakur H, De Backer D, , European society of intensive care medicine study of therapeutic hypothermia (32-35 °C) for intracranial pressure reduction after traumatic brain injury (the Eurotherm3235Trial)., Trials, 2011, 12, 8, doi: 10.1186/1745-6215-12-8.

  2. Results

    Andrews PJ, Sinclair LH, Harris B, Baldwin MJ, Battison CG, Rhodes JK, Murray G, De Backer D, , Study of therapeutic hypothermia (32 to 35°C) for intracranial pressure reduction after traumatic brain injury (the Eurotherm3235Trial): outcome of the pilot phase of the trial., Trials, 2013, 14, 277, doi: 10.1186/1745-6215-14-277.

Editorial Notes